PARP (Poly ADP‐ribose Polymerase) Family in Health and Disease
MedComm · 2025-09 · 6 (9)
DOI: 10.1002/mco2.70314 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, 2025-09. Verfasst von Pengyuan Lei und 9 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Key Laboratory for Radiobiology Department of Radiation Biology Beijing Institute of Radiation Medicine Beijing China. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 238 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The poly(ADP‐ribose) polymerase (PARP) family consists of 17 members of nicotinamide adenine dinucleotide (NAD⁺)‐dependent enzymes that regulate key biological processes by catalyzing adenosine diphosphate (ADP)‐ribosylation, either poly(ADP‐ribosyl)ation (PARylation) or mono(ADP‐ribosyl)ation (MARylation). These biological processes encompass DNA repair, metabolism, telomere maintenance, and immune responses. Based on structural and functional features, the PARP family is classified into subcategories, such as DNA‐dependent PARPs, Tankyrase, CCCH‐type PARPs, MacroPARPs, and atypical PARPs. These enzymes dynamically maintain genome stability through mechanisms, including base excision repair and homologous recombination, while also regulating telomere dynamics and metabolic pathways. Dysregulation of PARP activity is implicated in the pathogenesis of diverse human diseases. Though PARP inhibitors have gained therapeutic interest in oncology, their wider roles in nononcological conditions, such as neurodegenerative diseases, cardiovascular disorders, and viral infections, remain poorly defined. This review elucidates the unique structural features of PARP family members and describes their multiple roles under physiological and pathological conditions, thus providing insights into treatment strategies. Additionally, it summarizes the advances and challenges in PARP‐targeted therapies and explores future directions for innovative therapeutic approaches. The findings may serve as a valuable resource for informing both clinical research and drug development.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Beijing Key Laboratory for Radiobiology Department of Radiation Biology Beijing Institute of Radiation Medicine Beijing China.
- College of Public Health University of South China Hengyang Hunan China.
- Department of Occupational and Environmental Health Xiangya School of Public Health Central South University Changsha Hunan China.
- Hengyang Medical School University of South China Hengyang Hunan China.
ORCID-Profile: Pengyuan Lei
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Lei, P., Li, W., Luo, J., Xu, N., Wang, Y., Xie, D., Guan, H., Huang, B., Huang, X., & Zhou, P. (2025). PARP (Poly ADP‐ribose Polymerase) Family in Health and Disease. MedComm, 6(9). https://doi.org/10.1002/mco2.70314
Vancouver
Lei P, Li W, Luo J, Xu N, Wang Y, Xie D, et al. PARP (Poly ADP‐ribose Polymerase) Family in Health and Disease. MedComm. 2025;6(9). doi:10.1002/mco2.70314
BibTeX
@article{Lei2025,
author = {Lei, Pengyuan and Li, Wenfeng and Luo, Jinhua and Xu, Nanxin and Wang, Yahe and Xie, Dafei and Guan, Hua and Huang, Bo and Huang, Xin and Zhou, Pingkun},
title = {PARP (Poly ADP‐ribose Polymerase) Family in Health and Disease},
journal = {MedComm},
year = {2025},
volume = {6},
number = {9},
doi = {10.1002/mco2.70314}
}
EUVIMED